Journals / European Archives of Medical Research / 2021 / Cilt: 37 - Sayı: 4

The Efficacy of ${}^{18}F-FDG$ PET/CT in Detecting Colorectal Cancer Recurrences

Pages
236–243
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall success of the ${}^{18}F-FDG$ PET/CT in detecting recurrences in patients with elevated CEA levels and negative, equivocal and/or pathological findings of conventional imaging modalities was 70.6%.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Early diagnosis of recurrent colorectal cancer (CRC) has an impact on the patient’s survival and quality of life.
📊
Key Findings & Data:This study aimed to determine the efficacy of 18F-fluorodeoxyglucose (${}^{18}F-FDG$) positron emission tomography/computed tomography (PET/CT) imaging in restaging patients with previously operated CRC, with elevated tumor markers and/or suspicious, equivocal, or pathological conventional imaging modality findings.
💡
Conclusion & Impact:The overall success of the ${}^{18}F-FDG$ PET/CT in detecting recurrences in patients with elevated CEA levels and negative, equivocal and/or pathological findings of conventional imaging modalities was 70.6%.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Early diagnosis of recurrent colorectal cancer (CRC) has an impact on the patient’s survival and quality of life. This study aimed to determine the efficacy of 18F-fluorodeoxyglucose (${}^{18}F-FDG$) positron emission tomography/computed tomography (PET/CT) imaging in restaging patients with previously operated CRC, with elevated tumor markers and/or suspicious, equivocal, or pathological conventional imaging modality findings. Methods: Data of 75 patients (42 males, 33 females) with CRC were retrospectively analyzed. All patients had undergone an operation, with suspicion of recurrence because of elevated tumor markers and/or equivocal or pathological conventional imaging modality findings during follow-up. Only patients, who have undergone conventional imaging methods (CIM) (e.g., CT and magnetic resonance imaging) and/or with serum tumor marker (carcinoembryonic antigen) measurements done within the first month preceding the PET/CT scan, were included in the study. Results: Recurrence was confirmed in 58 patients with the clinical follow-up or pathological findings after the ${}^{18}F-FDG$ PET/CT imaging. The sensitivity, specificity, accuracy, and positive and negative predictive values of ${}^{18}F-FDG$ PET/CT in the diagnosis of CRC recurrence were 93.1%, 88.2%, 92%, 96.4%, and 78.9%, respectively. The ${}^{18}F-FDG$ PET/CT was superior to CIM and serum carcinoembryonic antigen (CEA) measurements in detecting recurrent diseases in patients with CRC. Conclusion: The ${}^{18}F-FDG$ PET/CT imaging was efficient for early detection of patients with recurrent CRC having elevated serum CEA levels. The overall success of the ${}^{18}F-FDG$ PET/CT in detecting recurrences in patients with elevated CEA levels and negative, equivocal and/or pathological findings of conventional imaging modalities was 70.6%. PET/CT exhibited a 93% success in detecting the recurrence in cases referred to ${}^{18}F-FDG$ PET/CT depending on suspicious findings on CIM and/or elevated CEA results. In our study, the ${}^{18}F-FDG$ PET/CT has changed the disease management in 33.3% of patients.

🔖

Cite This Article

ÖZÜLKER, T., GÜVELİ, T. K., UZUN, A. K., ÖZÜLKER, F. (2022). The Efficacy of ${}^{18}F-FDG$ PET/CT in Detecting Colorectal Cancer Recurrences. European Archives of Medical Research, Cilt: 37 - Sayı: 4, 236–243. https://ajindex.com/articles/510312

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009;59:225-49
  2. Flamen P, Stroobants S, Van Cutsem E, Dupont P, Bormans G, De Vadder N, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999;17:894-901
  3. Kalff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002;43:492-9
  4. Tepper JE, O’Connell M, Hollis D, Niedzwiecki D, Cooke E, Mayer RJ, et al. Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. J Clin Oncol 2003;21:3623- 8
  5. Goldberg RM, Fleming TR, Tangen CM, Moertel CG, Macdonald JS, Haller DG, et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med 1998;129:27-35
  6. Chong G, Cunningham D. Gastrointestinal cancer: recent developments in medical oncology. Eur J Surg Oncol 2005;31:453-60
  7. Punt CJ. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 2004;15:1453-9
  8. Bennett JJ, Cao D, Posner MC. Determinants of unresectability and outcome of patients with occult colorectal hepatic metastases. J Surg Oncol 2005;92:64-9
  9. Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-22
  10. Zervos EE, Badgwell BD, Burak WE Jr, Arnold MW, Martin EW. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery 2001;130:636-43; discussion 643-4
  11. Sarikaya I, Bloomston M, Povoski SP, Zhang J, Hall NC, Knopp MV, et al. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol 2007;5:64
  12. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA